Liquidia Co. (NASDAQ:LQDA) Insider Sells 2,260 Shares

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,260 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the transaction, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rajeev Saggar also recently made the following trade(s):

• On Friday, July 19th, Rajeev Saggar sold 1,873 shares of Liquidia stock. The shares were sold at an average price of $11.13, for a total value of $20,846.49.

Liquidia Stock Down 1.5 %

Shares of LQDA opened at $11.46 on Friday. The stock’s 50-day moving average price is $10.42 and its 200 day moving average price is $11.97. The firm has a market capitalization of $875.70 million, a price-to-earnings ratio of -7.35 and a beta of 0.22. Liquidia Co. has a 12-month low of $5.71 and a 12-month high of $16.99.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $3.66 million for the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. Equities research analysts expect that Liquidia Co. will post -1.69 EPS for the current year.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently made changes to their positions in LQDA. Patient Square Capital LP acquired a new stake in shares of Liquidia during the 1st quarter valued at about $105,942,000. Vanguard Group Inc. raised its position in Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after purchasing an additional 43,352 shares in the last quarter. Farallon Capital Management LLC bought a new position in Liquidia during the first quarter worth about $30,311,000. Whitefort Capital Management LP boosted its holdings in Liquidia by 45.8% during the first quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock valued at $4,980,000 after purchasing an additional 106,049 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after purchasing an additional 125,315 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LQDA. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Liquidia in a report on Monday, August 19th. Oppenheimer initiated coverage on shares of Liquidia in a report on Tuesday, June 25th. They set a “market perform” rating for the company. Bank of America dropped their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Lifesci Capital assumed coverage on Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).